Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma has extended its exclusive option agreement with the University of Maryland, Baltimore to investigate novel joint-homing peptides aimed at treating rheumatoid arthritis. This extension allows Silo more time to evaluate a potentially transformative therapeutic platform that could enhance drug delivery for traditional and psychedelic treatments, which may improve efficacy while reducing toxicity. CEO Eric Weisblum emphasized the significance of this technology for targeted therapy delivery.
Silo Pharma, Inc. (OTCQB: SILO) has entered a Scientific Research Agreement with the University of California San Francisco (UCSF) to explore the effects of psilocybin on inflammatory markers in patients with Parkinson's, Bipolar disorder, and chronic back pain. This agreement will utilize four other planned clinical trials by UCSF. CEO Eric Weisblum emphasized the potential of psilocybin to reduce inflammation related to these conditions, which may improve treatment outcomes. The study will be conducted at UCSF's Translational Psychedelic Research Program, focusing on the impact of psychedelics on various disorders.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its initial application to list on the NASDAQ Capital Market. This follows the board's prior approval to commence the up-listing process. The NASDAQ listing is contingent upon meeting regulatory requirements and acceptance by NASDAQ, which cannot be assured. CEO Eric Weisblum emphasized that a NASDAQ listing aims to enhance investor liquidity, attract institutional investors, and improve the company's visibility. Silo Pharma focuses on developing psychedelic therapies for conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its investigator-led study using Psilocybin for treating Parkinson’s disease for ethics board review in the Netherlands. CEO Eric Weisblum expressed satisfaction with this milestone and anticipates sharing more details with the scientific community and shareholders.
Silo Pharma is focused on merging traditional therapeutics with psychedelic research to assist patients suffering from conditions like depression, PTSD, and rare neurological disorders.
Silo Pharma (OTCQB: SILO) has announced a joint venture with Zylo Therapeutics to develop a sustained-release topical delivery system for ketamine and psilocybin. This collaboration aims to address the needs of patients with dysphagia, particularly those dealing with Alzheimer’s and Parkinson’s diseases. The ZTI’s Z-pod technology will enable the controlled delivery of these psychedelics, potentially reducing hallucinogenic effects while exploring their safety and efficacy. This initiative aligns with Silo Pharma's mission to innovate therapeutic solutions.
Silo Pharma, Inc. (OTCQB: SILO) announced its Board of Directors' unanimous decision to uplist to the NASDAQ. CEO Eric Weisblum emphasized that this move aims to enhance visibility and attract institutional investors, fostering long-term shareholder value. The uplisting is contingent upon meeting NASDAQ's listing requirements and securing approval. Silo Pharma focuses on developing psilocybin-based therapeutics for mental health issues and neurological disorders.
Silo Pharma, Inc. (OTCQB: SILO), a biopharmaceutical company focusing on psilocybin therapy, has finalized a sublicense agreement related to its provisional patent for CNS homing peptides aimed at treating pain from neuroinflammation in cancer patients. CEO Eric Weisblum expressed enthusiasm for the collaboration and emphasized the company's commitment to creating shareholder value while developing innovative therapeutics. The news comes on the heels of an earlier Letter of Intent from February, highlighting Silo's strategic growth.
Silo Pharma has entered an exclusive option agreement with the University of Maryland to investigate novel joint-homing peptides aimed at treating inflammation related to autoimmune diseases, specifically rheumatoid arthritis. These peptides could enhance drug delivery directly to affected joints, potentially increasing therapeutic efficacy while minimizing systemic toxicity. Silo's CEO emphasized the potential of this technology as a revolutionary drug delivery platform that meets the need for innovative treatments for patients with rare diseases.
Silo Pharma, a biopharmaceutical company, announced that CEO Eric Weisblum will present at Proactive's One2One Virtual Investor Forum on February 23, 2021, at 1 p.m. EST. The event is expected to reach Proactive's 20,000 YouTube subscribers and will be broadcasted globally. Silo Pharma focuses on merging traditional therapeutics with psychedelic research to address conditions such as depression, PTSD, and Parkinson's disease. The presentation will include a Q&A session and will be made available online after the event.
Silo Pharma has signed a Master License Agreement with the University of Maryland Baltimore to license innovative Central nervous system-homing peptides aimed at treating multiple sclerosis and other neuroinflammatory disorders. This agreement follows preclinical studies that support the peptide's efficacy. CEO Eric Weisblum emphasized Silo's commitment to merging traditional therapeutics with psychedelic research, suggesting potential benefits for patients with neurological conditions.